Hsp90 - a potential prognostic marker in CML

Blood Cells, Molecules, and Diseases

Volumn 50, Issue 3, 2013, Pages 184-189

  Žáčková, Markéta ^a   Moučková, Darina ^a   Lopotová, Tereza ^a,b   Ondráčková, Zuzana ^a   Klamová, Hana ^a   Moravcová, Jana ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Chronic myeloid leukemia; Heat shock proteins; Prognostic markers; Resistance

Indexed keywords

BCR ABL PROTEIN; DASATINIB; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; IMATINIB;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CELL LEVEL; CHRONIC MYELOID LEUKEMIA; COMPLETE MOLECULAR REMISSION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MAJOR CLINICAL STUDY; MAJOR MOLECULAR RESPONSE; MALE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; WESTERN BLOTTING;

ADULT; AGED; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; FUSION PROTEINS, BCR-ABL; HSP90 HEAT-SHOCK PROTEINS; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROGNOSIS; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84873259656     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2012.11.002     Document Type: Article

References (30)

1. Baccarani M., Cortes J., Pane F., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J. Clin. Oncol. 2009, 27:6041-6051.
2. Hochhaus A., O'Brien S.G., Guilhot F., et al. Six-year followup of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23:1054-1061.
3. Wu J., Meng F., Lu H., Kong L., Bornmann W., Peng Z., Talpaz M., Donato N.J. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood 2008, 111:3821-3829.
4. Mauro M.J. Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Cancer Control 2009, 16(2):108-121.
5. Henderson B. Integrating the cell stress response: a new view of molecular chaperones as immunological and physiological homeostatic regulators. Cell Biochem. Funct. 2010, 28:1-14.
6. Kawakami H., Tomita M., Okudaira T., Ishikawa Ch., Matsuda T., Tanaka Y., Nakazato T., Taira N., Ohshiro K., Mori N. Inhibition of heat shock protein-90 modulates multiple functions required for survival of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells. Int. J. Cancer 2007, 120:1811-1820.
7. Neckers L. Heat shock protein 90: the cancer chaperone. J. Biosci. 2007, 32:517-530.
8. Trepel J., Mollapour M., Giaccone G., Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 2010, 10:537-549.
9. An W.G., Schulte T.W., Neckers L.M. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ. 2000, 11:355-360.
10. Wu L.X., Xu J.H., Zhang K.Z., Lin Q., Huang X.W., Wen C.X., Chen Y.Z. Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin. Leukemia 2008, 22:1402-1409.
11. Guo F., Sigua C., Bali P., George P., Fiskus W., Scuto A., Annavarapu S., Mouttaki A., Sondarva G., Wei S., Wu J., Djeu J., Bhalla K. Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood 2005, 105:1246-1255.
12. Pocaly M., Lagarde V., Etienne G., Ribeil J.A., Claverol S., Bonneu M., Moreau-Gaudry F., Guyonnet-Duperat V., Hermine O., Melo J.V., Dupouy M., Turcq B., Mahon F.X., Pasquet J.M. Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia. Leukemia 2007, 21:93-101.
13. Pratt W.B., Toft D.O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. 2003, 228:111-133.
14. Hernandez M.P., Sullivan W.P., Toft D.O. The assembly and intermolecular properties of the hsp70-Hop-hsp90 molecular chaperone complex. J. Biol. Chem. 2002, 277:38294-38304.
15. Marfe G., Pucci B., De Martino L., et al. Heat-shock protein pretreatment inhibits sorbitol-induced apoptosis in K562, U937 and HeLa cells. Int. J. Cancer 2009, 125:2077-2085.
16. Larroca L.M., Ranelletti F.O., Maggiano N., et al. Differential sensitivity of leukemic and normal hematopoietic progenitors to the killing effect of hyperthermia and quercetinused in combination: role of heat-shock protein-70. Int. J. Cancer 1997, 73:75-83.
17. Afanasyeva E.A., Komarova E.Y., Larsson L.-G., et al. Drug-induced Myc-mediated apoptosis of cancer cells is inhibited by stress protein HSP70. Int. J. Cancer 2007, 121:2615-2621.
18. Blagosklonny M.V., Fojo T., Bhalla K.N., Kim J.-S., Trepel J.B., Figg W.D., Rivera Y., Neckers L.M. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia 2001, 15:1537-1543.
19. Gorre M.E., Ellwood-Yen K., Chiosis G., Rosen N., Sawyers C.L. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002, 100:3041-3044.
20. Donnelly A., Blagg B.S.J. Novobiocin additional inhibitors of the HSP90 C-terminal nuckleotide-binding pocket. Curr. Med. Chem. 2008, 15:2701-2717.
21. Beck R., Verrax J., Gonze T., Zappone M., Pedrosa R.C., Taper H., Feron O., Calderon P.B. HSP 90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death. Biochem. Pharmacol. 2009, 77(3):375-383.
22. Goetz M.P., Toft D.O., Ammes M.M., Erlichman C. The Hsp90 complex as a novel target for cancer therapy. Ann. Oncol. 2003, 14:1169-1176.
23. Scheibela T., Buchnera J. The Hsp90 complex-a super-chaperone machine as a novel drug target. Biochem. Pharmacol. 1998, 56(6):675-682.
24. Gabert J., Beillard E., van der Velden V.H., et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003, 17(12):2318-2357.
25. Rulcová J., Zmeková V., Zemanová Z., Klamová H., Moravcová J. The effect of total-ABL, GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR. Leuk. Res. 2007, 31:483-491.
26. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
27. Tsutsumi Shinji, Neckers Len Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci. 2007, 98(10):1536-1539.
28. Yeh C.H., Tseng R., Zhang Z., Cortes J., O'Brien S., Giles F., Hannah A., Estrov Z., Keating M., Kantarjian H., Albitar M. Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia. Leuk. Res. 2009, 33:212-217.
29. Calderwood S.K., Mambula S.S., Gray P.J. Extracellular heat shock proteins in cell signaling and immunity. Ann. N. Y. Acad. Sci. 2007, 1113:28-39.
30. Rohon P., Faber E., Divoka M., Rozmanova S., Friedecky D., Jarosova M., Indrak K. A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub. Nov 30 2011, (Epub ahead of print). 10.5507/bp.2011.059.